Delivery Order SPE2DB25D3012-SPE2DB25FWYTN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,687.18 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors. This competitive award, issued on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a firm fixed-price transaction under a non-set-aside procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency (DLA) awarded a $14,061.54 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pens on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract utilizes no set-aside designation and represents a competitively awarded delivery order under the company's existing indefinite delivery contract with DLA. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injections, with an ultimate completion date of August 8, 2025. This non-set-aside contract, awarded on July 18, 2025, represents a single delivery order fulfillment executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a $2,343.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injectors, with a completion date of August 11, 2025. This non-set-aside contract was competitively awarded on July 21, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE is a specialty biologic medication used in the treatment of moderate-to-severe asthma, reflecting DLA's ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 21, 2025, for TEZSPIRE 210 mg/1.91 mL pen auto-injectors. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of August 11, 2025. The contract will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 MG/1.91 ML pen injectables, with performance through August 15, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $9,374.36 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pens on July 25, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order is unset-aside and competitively awarded, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a monoclonal antibody biologic used in asthma and chronic rhinosinusitis treatment, representing part of...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18, with completion scheduled for August 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract is not set aside for any socioeconomic category and is scheduled for completion by August 12, 2025. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pens. The contract, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by August 12, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWYTNDelivery Order
The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pens on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price contract utilizes no set-aside designation and represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TEZSPIRE is a biologic medication used for the treatment of moderate-to-severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor supporting military and defense healthcare systems. The company maintains an extensive portfolio of federal medical supply contracts with DLA, delivering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities worldwide through the comprehensive Pharmaceutical Prime Vendor Global Program vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 7/22/25 |